埃奎利祖马布在硬质瘤中使用 结血小血管病的危机:一个案例报告
Claire Trivin-Avillach1, Aala Jaberi2, Joel M Henderson1
1Department of Pathology and Laboratory Medicine, Boston Medical Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA.
Kidney medicine
|January 16, 2024
概括
一个高血压患者的硬化硬化性危机通过补充抑制剂eculizumab快速改善,证明了其在治疗严重损伤和血栓性微血管病变中的有效性.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 类风湿病学 类风湿病学
- 血液学 血液学 血液学
背景情况:
- 系统性硬化无线性硬化症可以出现严重的高血压和急性损伤.
- 结核病危机是一种危及生命的并发症,其特征是血栓性微血管病变.
- 早期诊断和干预对于管理多发性硬皮症危机至关重要.
研究的目的:
- 报告一个用eculizumab成功治疗硬化肌性危机的病例.
- 突出终端补体阻塞在治疗严重血栓性微血管病变中的作用.
- 为了证明功能恢复的潜力,在多发性硬化的危机.
主要方法:
- 一名患有硬质皮质危机的患者接受了高剂量的ACE抑制剂治疗和血压控制.
- 一个脏活检证实了严重的硬质皮质脏危机与活跃的血栓式微血管病变.
- 治疗被升级为包括eculizumab (终端补体阻塞).
主要成果:
- 治疗eculizumab导致功能显著改善,血清肌素从9.3 mg/dL的峰值下降到治疗后的2.8 mg/dL和3年随访后的1.8 mg/dL.
- 患者的血压和体积状况稳定.
- 系统性微血管病性血清性贫血的证据得到解决.
结论:
- 用eculizumab进行终端补充阻塞是严重的硬质皮质性危机的有前途的治疗选择.
- 在这种情况下,eculizumab可以逆转急性损伤和血栓性微血管病变.
- 积极的治疗,包括新疗法,可以导致长期恢复功能.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
166
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
166
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
139
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
139


![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)